Abstract
Generally, calcitonin (CT) values below the upper reference limit rule-out medullary thyroid carcinoma (MTC) with very high accuracy. However, sparse cases of serum-calcitonin-negative MTC (CT-NEG-MTC) have been reported. Here we reviewed CT-NEG-MTC reported in literature, discussed the potential causes and proposed a practical laboratory and clinical approach. A comprehensive literature search was conducted by using the terms “medullary thyroid carcinoma” AND “non-secreting calcitonin” OR “undetectable calcitonin”. The search was updated until December 2014. Original articles that described CT-NEG-MTC were eligible for inclusion. Only MTC cases with preoperative CT below the upper reference limit were included in the present review. Eleven papers with 18 CT-NEG-MTC cases (age 50 years, size 26 mm) were retrieved. Four patients with poorly differentiated MTC died within 3 years. Different CT assays were employed and different reference values were adopted. Preoperative serum CT values were below the institution cut-off levels in all cases, and undetectable in four patients. In some papers negative CT results were confirmed by additional tests. Further laboratory investigations were performed in some of the included studies. In patients with well founded suspicious of MTC and within the reference limits/undetectable CT other laboratory investigations [carcinoembryonic antigen (CEA), procalcitonin, CT stimulation, CT in washout of nodule’s aspiration] have to be performed. Surgical approach to CT-NEG-MTC does not differ from those secreting CT. Postoperative follow-up of these rare cases should include periodical imaging and measurement of all potential markers. Patients with poorly differentiated MTC are at higher risk of disease-related death, and require more aggressive follow-up strategy.
References
1. Kloos RT, Eng C, Evans DB, Francis GL, Gagel RF, Gharib H, et al. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid 2009;19:565–612.10.1089/thy.2008.0403Search in Google Scholar PubMed
2. Gharib H, Papini E, Paschke R, Duick DS, Valcavi R, Hegedüs L, et al. American Association of Clinical Endocrinologists, Associazione Medici Endocrinologi, and European Thyroid Association medical guidelines for clinical practice for the diagnosis and management of thyroid nodules. Endocr Pract 2010;16:468–75.10.4158/EP.16.3.468Search in Google Scholar PubMed
3. Pusztaszeri MP, Bongiovanni M, Faquin WC. Update on the cytologic and molecular features of medullary thyroid carcinoma. Adv Anat Pathol 2014;21:26–35.10.1097/PAP.0000000000000004Search in Google Scholar PubMed
4. Trimboli P, Treglia G, Guidobaldi L, Romanelli F, Nigri G, Valabrega S, et al. Detection rate of FNA cytology in medullary thyroid carcinoma: a meta-analysis. Clin Endocrinol (Oxf) 2015;82:280–5.10.1111/cen.12563Search in Google Scholar PubMed
5. Elisei R, Bottici V, Luchetti F, Di Coscio G, Romei C, Grasso L, et al. Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10,864 patients with nodular thyroid disorders. J Clin Endocrinol Metab 2004;89:163–8.10.1210/jc.2003-030550Search in Google Scholar PubMed
6. Bugalho MJ, Santos JR, Sobrinho L. Preoperative diagnosis of medullary thyroid carcinoma: fine needle aspiration cytology as compared with serum calcitonin measurement. J Surg Oncol 2005;91:56–60.10.1002/jso.20269Search in Google Scholar PubMed
7. Boi F, Maurelli I, Pinna G, Atzeni F, Piga M, Lai ML, et al. Calcitonin measurement in wash-out fluid from fine needle aspiration of neck masses in patients with primary and metastatic medullary thyroid carcinoma. J Clin Endocrinol Metab 2007;92:2115–8.10.1210/jc.2007-0326Search in Google Scholar PubMed
8. Kudo T, Miyauchi A, Ito Y, Takamura Y, Amino N, Hirokawa M. Diagnosis of medullary thyroid carcinoma by calcitonin measurement in fine-needle aspiration biopsy specimens. Thyroid 2007;17:63–8.10.1089/thy.2006.0338Search in Google Scholar PubMed
9. Essig GF Jr., Porter K, Schneider D, Debora A, Lindsey SC, Busonero G, et al. Fine needle aspiration and medullary thyroid carcinoma: the risk of inadequate preoperative evaluation and initial surgery when relying upon FNAB cytology alone. Endocr Pract 2013;19:920–7.10.4158/EP13143.ORSearch in Google Scholar PubMed
10. Jo VY, Renshaw AA, Krane JF. Relative sensitivity of thyroid fine-needle aspiration by tumor type and size. Diagn Cytopathol 2013;41:871–5.Search in Google Scholar
11. Trimboli P, Cremonini N, Ceriani L, Saggiorato E, Guidobaldi L, Romanelli F, et al. Calcitonin measurement in aspiration needle washout fluids has higher sensitivity than cytology in detecting medullary thyroid cancer: a retrospective multicentre study. Clin Endocrinol (Oxf) 2014;80:135–40.10.1111/cen.12234Search in Google Scholar PubMed
12. Kim SH, Kim BS, Jung SL, Lee JW, Yang PS, Kang BJ, et al. Ultrasonographic findings of medullary thyroid carcinoma: a comparison with papillary thyroid carcinoma. Korean J Radiol 2009;10:101–5.10.3348/kjr.2009.10.2.101Search in Google Scholar PubMed PubMed Central
13. Lee S, Shin JH, Han BK, Ko EY. Medullary thyroid carcinoma: comparison with papillary thyroid carcinoma and application of current sonographic criteria. Am J Roentgenol 2010;194:1090–4.10.2214/AJR.09.3276Search in Google Scholar PubMed
14. Choi N, Moon WJ, Lee JH, Baek JH, Kim DW, Park SW. Ultrasonographic findings of medullary thyroid cancer: differences according to tumor size and correlation with fine needle aspiration results. Acta Radiol 2011;52:312–6.10.1258/ar.2010.100247Search in Google Scholar PubMed
15. Trimboli P, Nasrollah N, Amendola S, Rossi F, Ramacciato G, Romanelli F, et al. Should we use ultrasound features associated with papillary thyroid cancer in diagnosing medullary thyroid cancer? Endocr J 2012;59:503–8.10.1507/endocrj.EJ12-0050Search in Google Scholar PubMed
16. Andrioli M, Trimboli P, Amendola S, Valabrega S, Fukunari N, Mirella M, et al. Elastographic presentation of medullary thyroid carcinoma. Endocr 2014;45:153–5.10.1007/s12020-013-0062-4Search in Google Scholar PubMed
17. Fukushima M, Ito Y, Hirokawa M, Miya A, Kobayashi K, Akasu H, et al. Excellent prognosis of patients with nonhereditary medullary thyroid carcinoma with ultrasonographic findings of follicular tumor or benign nodule. World J Surg 2009;33:963–8.10.1007/s00268-009-9939-zSearch in Google Scholar PubMed
18. Trimboli P, Giovanella L, Valabrega S, Andrioli M, Baldelli R, Cremonini N, et al. Ultrasound features of medullary thyroid carcinoma correlate with cancer aggressiveness: a retrospective multicenter study. J Exp Clin Cancer Res 2014;33:87.10.1186/s13046-014-0087-4Search in Google Scholar PubMed PubMed Central
19. Trimboli P, Giovanella L, Crescenzi A, Romanelli F, Valabrega S, Spriano G, et al. Medullary thyroid cancer diagnosis: an appraisal. Head Neck 2014;36:1216–23.10.1002/hed.23449Search in Google Scholar PubMed
20. Iglesias P, Vicandi B, Ortega P, Díez JJ. Variante anaplásica del carcinoma medular de tiroides. Med Clín (Barc) 1997;109:276.Search in Google Scholar
21. Niccoli P, Wion-Barbot N, Caron P, Henry JF, de Micco C, Saint Andre JP, et al. Interest of routine measurement of serum calcitonin: study in a large series of thyroidectomized patients. The French Medullary Study Group. Clin Endocrinol Metab 1997;82:338–41.10.1210/jcem.82.2.3737Search in Google Scholar PubMed
22. Redding AH, Levine SN, Fowler MR. Normal preoperative calcitonin levels do not always exclude medullary thyroid carcinoma in patients with large palpable thyroid masses. Thyroid 2000;10:919–22.10.1089/thy.2000.10.919Search in Google Scholar PubMed
23. Bockhorn M, Frilling A, Rewerk S, Liedke M, Dirsch O, Schmid KW, et al. Lack of elevated serum carcinoembryonic antigen and calcitonin in medullary thyroid carcinoma. Thyroid 2004;14:468–70.10.1089/105072504323150813Search in Google Scholar PubMed
24. Sand M, Gelos M, Sand D, Bechara FG, Bonhag G, Welsing E, et al. Serum calcitonin negative medullary thyroid carcinoma. W J Surg Oncol 2006;4:97.10.1186/1477-7819-4-97Search in Google Scholar PubMed PubMed Central
25. Dora JM, Canalli MH, Capp C, Punales MK, Vieira JG, Maia AL. Normal perioperative serum calcitonin levels in patients with advanced medullary thyroid carcinoma: case report and review of the literature. Thyroid 2008;18:895–9.10.1089/thy.2007.0231Search in Google Scholar PubMed
26. Giovanella L, Crippa S, Cariani L. Serum calcitonin-negative medullary thyroid carcinoma: role of CgA and CEA as complementary markers. Int J Biol Markers 2008;23:129–31.10.1177/172460080802300212Search in Google Scholar
27. Alapat DV, Ain KB, Sloan DA, Monaghan KG, Karabakhtsian RG. Disparity between tissue and serum calcitonin and carcinoembryonic antigen in a patient with medullary thyroid carcinoma. Endocr 2011;39:148–52.10.1007/s12020-010-9433-2Search in Google Scholar PubMed
28. Chambon G, Alovisetti C, Idoux-Louche C, Reynaud C, Rodier M, Guedj AM, et al. The use of preoperative routine measurement of basal serum thyrocalcitonin in candidates for thyroidectomy due to nodular thyroid disorders: results from 2733 consecutive patients. J Clin Endocrinol Metab 2011;96:75–81.10.1210/jc.2010-0162Search in Google Scholar PubMed
29. Frank-Raue K, Machens A, Leidig-Bruckner G, Rondot S, Haag C, Schulze E, et al. Prevalence and clinical spectrum of nonsecretory medullary thyroid carcinoma in a series of 839 patients with sporadic medullary thyroid carcinoma. Thyroid 2013;23:294–300.10.1089/thy.2012.0236Search in Google Scholar PubMed
30. Brutsaert EF, Gersten AJ, Tassler AB, Surks MI. Medullary thyroid cancer with undetectable serum calcitonin. J Clin Endocrinol Metab 2015;100:337–41.10.1210/jc.2014-3095Search in Google Scholar PubMed
31. Costante G, Meringolo D, Durante C, Bianchi D, Nocera M, Tumino S, et al. Predictive value of serum calcitonin levels for preoperative diagnosis of medullary thyroid carcinoma in a cohort of 5817 consecutive patients with thyroid nodules. J Clin Endocrinol Metab 2007;92:450–5.10.1210/jc.2006-1590Search in Google Scholar PubMed
32. Cheung K, Roman SA, Wang TS, Walker HD, Sosa JA. Calcitonin measurement in the evaluation of thyroid nodules in the United States: a cost-effectiveness and decision analysis. J Clin Endocrinol Metab 2008;93:2173–80.10.1210/jc.2007-2496Search in Google Scholar PubMed
33. Saller B, Görges R, Reinhardt W, Haupt K, Janssen OE, Mann K. Sensitive calcitonin measurement by two-site immunometric assays: implications for calcitonin screening in nodular thyroid disease. Clin Lab 2002;48:191–200.Search in Google Scholar
34. Perdrisot R, Bigorgne JC, Guilloteau D, Jallet P. Monoclonal immunoradiometric assay of calcitonin improves investigation of familial medullary thyroid carcinoma. Clin Chem 1990;36:381–3.10.1093/clinchem/36.2.381Search in Google Scholar
35. Zink A, Blind E, Raue F. Determination of serum calcitonin by immunoradiometric two-site assays in normal subjects and patients with medullary thyroid carcinoma. Eur J Clin Chem Clin Biochem 1992;30:831–5.Search in Google Scholar
36. Grauer R, Raue F, Ziegler R. Clinical usefulness of a new chemiluminescent two-site immunoassay for human calcitonin. Exp Clin Endocrinol Diabetes 1998;106:353–9.10.1055/s-0029-1211997Search in Google Scholar PubMed
37. Leboeuf R, Langlois MF, Martin M, Ahnadi CE, Fink GD. “Hook effect” in calcitonin immunoradiometric assay in patients with metastatic medullary thyroid carcinoma: case report and review of the literature. J Clin Endocrinol Metab 2006;91:361–4.10.1210/jc.2005-1429Search in Google Scholar PubMed
38. Bieglmayer C, Vierhapper H, Dudczack R, Niederle B. Measurement of calcitonin by immunoassay analyzers. Clin Chem Lab Med 2007;45:662–6.10.1515/CCLM.2007.124Search in Google Scholar PubMed
39. Karges W, Dralle HH, Raue F, Mann K, Reiners C, Grussendorf M, et al. German Society for Endocrinology (DGE): thyroid section. Calcitonin measurement to detect medullary thyroid carcinoma in nodular goiter: German evidence-based consensus recommendation. Exp Clin Endocrinol Diabetes 2004;112: 525–8.10.1055/s-2004-815727Search in Google Scholar PubMed
40. d’Herbomez M, Caron P, Bauters C, Do Cao C, Schlienger JL, Sapin R, et al. Reference range of serum calcitonin levels in humans: influence of calcitonin assays, sex, age, and cigarette smoking. Eur J Endocrinol 2007;157:749–55.10.1530/EJE-07-0566Search in Google Scholar PubMed
41. Giovanella L, Imperiali M, Ferrari A, Palumbo A, Lippa L, Peretti A, et al. Thyroid volume influences serum calcitonin levels in a thyroid-healthy population: results of a 3-assay, 519 subjects study. Clin Chem Lab Med 2012;50:895–900.10.1515/cclm-2011-0920Search in Google Scholar PubMed
42. Giovanella L. Serum procalcitonin and calcitonin normal values before and after calcium gluconate infusion. Exp Clin Endocrinol Diabet 2012;120:169–70.10.1055/s-0031-1301290Search in Google Scholar PubMed
43. Algeciras-Schimnich A, Preissenr CM, Theobald P, Finseth MS, Grebe SK. Procalcitonin: a marker for the diagnosis and follow-up of patients with medullary thyroid carcinoma. J Clin Endocrinol Metab 2009;94:861–8.10.1210/jc.2008-1862Search in Google Scholar PubMed PubMed Central
44. Giovanella L, Maffioli M, Suriano S, Dorizzi RM. Elevated calcitonin and procalcitonin levels in nonmedullary benign and malignant thyroid nodules. Clin Endocrinol 2010;72:852–3.10.1111/j.1365-2265.2009.03733.xSearch in Google Scholar PubMed
45. Kratzsch J, Petzold A, Raue F, Reinhardt W, Bröcker-Preuss M, Görges R, et al. Basal and stimulated calcitonin and procalcitonin in various assays in patients with and without medullary thyroid cancer. Clin Chem 2011;57:467–74.10.1373/clinchem.2010.151688Search in Google Scholar PubMed
46. Giovanella L, Verburg FA, Imperiali M, Valabrega S, Trimboli P, Ceriani L. Comparison of serum calcitonin and procalcitonin in detecting medullary thyroid carcinoma among patients with thyroid nodules. Clin Chem Lab Med 2012;51:1477–81.Search in Google Scholar
47. Machens A, Ukkat J, Hauptmann S, Dralle H. Abnormal carcinoembryonic antigen levels and medullary thyroid cancer progression: a multivariate analysis. Arch Surg 2007;142:289–93.10.1001/archsurg.142.3.289Search in Google Scholar PubMed
48. Mian C, Perrino M, Colombo C, Cavedon E, Pennelli G, Ferrero S, et al. Refining calcium test for the diagnosis of medullary thyroid cancer: cutoffs, procedures, and safety. J Clin Endocrinol Metab 2014;99:1656–64.10.1210/jc.2013-4088Search in Google Scholar PubMed
49. Machens A, Lorenz K, Dralle H. Utility of serum procalcitonin for screening and risk stratification of medullary thyroid cancer. J Clin Endocrinol Metab 2014;99:2986–94.10.1210/jc.2014-1278Search in Google Scholar PubMed
50. Trimboli P, Guidobaldi L, Crescenzi A, Bongiovanni M, Giovanella L. The essential use of FNA-calcitonin for detecting medullary thyroid cancer. Endocr 2014;47:342–4.10.1007/s12020-014-0226-xSearch in Google Scholar PubMed
©2015 by De Gruyter
